Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer

NCT03650894 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT03650894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03650894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Lead sponsor
Providence Health & Services
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 3, 2019
Completion date
December 31, 2026
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast carcinoma, breast neoplasm female, breast tumor